Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar Combined With Paclitaxel and Nedaplatin in Esophageal Cancer
NCT02350517Phase 2Completed
- Start
- Jan 2015
- Primary completion
- Dec 2019
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of endostar in Esophageal Squamous Cell Carcinoma (ESCC). Primary endpoint: Progression free survival at 24 months. Started Jan 2015; status: completed.
02
Drugs
endostar
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02350517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02350517.